Immuneering reports positive Phase 2a data for IMM-1-104 in pancreatic cancer; cash runway into 2026

Immuneering Corp

Phase 2a data: IMM-1-104 + mGnP showed 43% ORR, 86% DCR; + mFFX showed 50% ORR vs historic 23% and 32%.
Planning underway for potential global pivotal trial of IMM-1-104 in first-line pancreatic cancer.
Cash $36.1M at Dec 31, 2024; plus $13.7M from ATM in Jan 2025; runway into 2026.
Named Dr. Igor Matushansky as Chief Medical Officer to lead clinical programs.
Phase 1 pancreatic cancer patient on IMM-1-104 monotherapy for 13+ months with stable disease and 91% CA 19-9 reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.